Interstitial lung disease and pneumonitis have been reported more often in patients receiving vandetanib as compared to those receiving placebo; fatal adverse reactions for patients receiving vandetanib (2%) were respiratory failure and arrest, aspiration pneumonia, cardiac failure with arrhythmia, and sepsis